Overview

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-30
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
Phase:
PHASE1
Details
Lead Sponsor:
TerSera Therapeutics LLC
Treatments:
Goserelin